Designated Drug Use Investigation (12 Weeks) of Zetia [ezetimibe] 10mg Tablets - A 12-Week Designated Drug Use Investigation of Zetia Monotherapy and Combination Therapy.

Trial Profile

Designated Drug Use Investigation (12 Weeks) of Zetia [ezetimibe] 10mg Tablets - A 12-Week Designated Drug Use Investigation of Zetia Monotherapy and Combination Therapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 May 2014

At a glance

  • Drugs Ezetimibe (Primary) ; Antihyperlipidaemics
  • Indications Hypercholesterolaemia; Hyperlipoproteinaemia type II; Sitosterolaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 04 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Nov 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
    • 27 Jul 2008 The expected completion date for this trial is now 1 Jun 2009 according to clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top